<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vaccination for the prevention of chickenpox (primary varicella infection)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vaccination for the prevention of chickenpox (primary varicella infection)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Vaccination for the prevention of chickenpox (primary varicella infection)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mary A Albrecht, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary infection with varicella zoster virus (VZV) causes varicella (chickenpox) in susceptible hosts. While varicella is a self-limited infection in most healthy children, the incidence of hospitalization and even mortality in selected groups is significant. Varicella can cause significant complications, such as soft tissue infection, pneumonia, hepatitis, and encephalitis. Patients at increased risk of complications include adults, pregnant women, and immunocompromised hosts. </p><p>The use of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> to prevent primary varicella infection will be discussed here. Post-exposure prophylaxis to prevent primary varicella infection, the clinical manifestations and treatment of primary varicella infection, and the use of the zoster vaccine to prevent herpes zoster are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8273.html" rel="external">"Post-exposure prophylaxis against varicella-zoster virus infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8284.html" rel="external">"Clinical features of varicella-zoster virus infection: Chickenpox"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4969.html" rel="external">"Varicella-zoster infection in the newborn"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8331.html" rel="external">"Varicella-zoster virus infection in pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8336.html" rel="external">"Treatment of varicella (chickenpox) infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)"</a>.)</p><p></p><p class="headingAnchor" id="H519048387"><span class="h1">BENEFITS OF IMMUNIZATION</span><span class="headingEndMark"> — </span>Systematic reviews, randomized trials, and observational studies from a variety of countries indicate that routine immunization against varicella zoster virus (VZV) prevents varicella (chickenpox)  (<a class="graphic graphic_figure graphicRef105388" href="/d/graphic/105388.html" rel="external">figure 1</a>), reduces disease severity in breakthrough cases, reduces the risk of transmission [<a href="#rid1">1-12</a>], reduces varicella-associated health care utilization [<a href="#rid13">13</a>], and is associated with decreased risk of herpes zoster (shingles) in children [<a href="#rid14">14-16</a>]. Herd immunity extends protection to infants too young to be vaccinated and unvaccinated adults [<a href="#rid17">17-19</a>]. </p><p>In two systematic reviews of ≥40 studies of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> effectiveness, a single dose of varicella vaccine had an approximate effectiveness of [<a href="#rid20">20,21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>80 percent in preventing varicella disease of any severity </p><p class="bulletIndent1"><span class="glyph">●</span>95 to 98 percent in preventing moderate (generally defined by 50 to 500 lesions) or severe disease (generally defined by &gt;500 lesions, complications requiring medical care, hospitalization, or death)</p><p class="bulletIndent1"><span class="glyph">●</span>≥99 percent in preventing severe disease</p><p></p><p>Two doses appeared to be more effective than one dose in preventing varicella disease of any severity, providing a mean effectiveness of approximately 92 to 93 percent (range 84 to 98 percent) [<a href="#rid20">20,21</a>].</p><p>In surveillance from four states in the United States with continuous passive surveillance between 1995 and 2019, routine childhood immunization with varicella was associated with a &gt;97 percent decline in the incidence of varicella [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/8304.html" rel="external">"Epidemiology of varicella-zoster virus infection: Chickenpox", section on 'Epidemiology of disease after introduction of varicella vaccine'</a>.)</p><p>Vaccination after an exposure to varicella also decreases the risk of infection and the severity of disease [<a href="#rid23">23</a>]. The use of vaccination for post-exposure prophylaxis is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/8273.html" rel="external">"Post-exposure prophylaxis against varicella-zoster virus infection", section on 'Administration'</a> and  <a class="medical medical_review" href="/d/html/4047.html" rel="external">"Prevention and control of varicella-zoster virus in hospitals", section on 'Post-exposure prophylaxis'</a>.)</p><p class="headingAnchor" id="H519049166"><span class="h1">EVIDENCE OF IMMUNITY</span><span class="headingEndMark"> — </span>Evidence of immunity to varicella includes any of the following [<a href="#rid24">24,25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Documentation of age-appropriate varicella immunization:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children &lt;4 years – One dose after age 12 months</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children ≥4 years, adolescents, and adults – Two doses separated by at least 28 days and administered after age 12 months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory evidence of immunity or laboratory confirmation of disease; commercially available antibody assays detect disease-induced antibody, but may not reliably detect vaccine-induced antibody (see <a class="local">'Post-vaccination serology'</a> below and  <a class="medical medical_review" href="/d/html/8329.html" rel="external">"Diagnosis of varicella-zoster virus infection"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis or verification of prior typical varicella infection or herpes zoster infection by a health care provider. </p><p></p><p class="bulletIndent1">For people reporting a history of mild or atypical varicella (often having occurred in infants younger than one year), verification requires: 1) documentation of an epidemiologic link to a typical case or to a laboratory confirmed case; or 2) laboratory confirmation of the previous episode, because other diseases can mimic mild or atypical varicella.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For people born in the United States – Birth before 1980 (when the prevalence of varicella disease was high) <strong>unless</strong> they are immunosuppressed, pregnant, or a health care worker (such individuals must have serologic evidence of immunity, documentation of completed immunization, or verification of typical disease because they are at high risk of being exposed to varicella, are more likely to develop severe infection, and/or are likely to transmit varicella to those at risk for severe disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>People born outside the United States before 1980 must satisfy one of the other criteria for evidence of immunity because the prevalence of varicella in the country of origin may not be known. </p><p></p><p class="headingAnchor" id="H4"><span class="h1">INDICATIONS AND SCHEDULES</span></p><p class="headingAnchor" id="H519049481"><span class="h2">Priority groups</span><span class="headingEndMark"> — </span>Even though some countries recommend universal varicella vaccination, to prevent severe or complicated varicella infection in high-risk groups, and to prevent outbreaks, it is particularly important to immunize people who [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Have close contact with people at high risk for severe disease (eg, health care workers and household contacts of immunocompromised people)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Are at high risk for exposure or transmission, including: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Teachers of young children</p><p class="bulletIndent2"><span class="glyph">•</span>Child care employees</p><p class="bulletIndent2"><span class="glyph">•</span>Residents and staff members of institutional settings, including correctional institutions</p><p class="bulletIndent2"><span class="glyph">•</span>College students</p><p class="bulletIndent2"><span class="glyph">•</span>Military personnel</p><p class="bulletIndent2"><span class="glyph">•</span>Adolescents and adults living in households with children</p><p class="bulletIndent2"><span class="glyph">•</span>Nonpregnant women of childbearing age</p><p class="bulletIndent2"><span class="glyph">•</span>International travelers </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Are immigrants and refugees [<a href="#rid26">26-29</a>]</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Schedules in the United States</span><span class="headingEndMark"> — </span>Two doses of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> are recommended for routine immunization of immunocompetent children, adolescents, and adults without evidence of immunity [<a href="#rid24">24,30,31</a>]. The recommended routine and "catch-up" schedules vary according to age. (See <a class="local">'Evidence of immunity'</a> above and <a class="local">'Children &lt;13 years'</a> below and <a class="local">'Adolescents and adults'</a> below.)</p><p>Immunization of immunocompromised patients should be undertaken with expert guidance and consultation. (See <a class="local">'Immunocompromised hosts'</a> below.)</p><p>The United States switched from a one-dose to a two-dose schedule in 2007 [<a href="#rid24">24</a>]. Despite a single-dose effectiveness of &gt;80 percent, outbreaks of varicella continued to occur in highly vaccinated populations [<a href="#rid32">32-34</a>]. The second dose was added to stimulate an immune response in the up to 25 percent of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> recipients who fail to respond to a single dose [<a href="#rid24">24,35,36</a>]. Compared with a single dose, two doses of varicella vaccine are associated with increased rates of seroconversion, increased antibody titers, increased effectiveness, and longer lasting immunity [<a href="#rid1">1,4,10,37-44</a>]. (See <a class="local">'Breakthrough varicella'</a> below.)</p><p>The superiority of the two-dose schedule was demonstrated in a multicenter randomized trial in 5285 healthy children age 12 to 22 months [<a href="#rid39">39</a>]. The efficacy of two doses of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> (administered as MMRV) in preventing laboratory or epidemiologically confirmed varicella was 95 percent (97.5% CI 92-97 percent) and the efficacy of a single dose was 65 percent (97.5% CI 57-72 percent). Breakthrough infection was seven times (95% CI 5-10 times) less likely with two doses than with a single dose. In addition, the overall incidence of varicella decreased by 85 percent after the two-dose schedule was instituted (from 25.4 per 100,000 population during 2005-2006 to 3.9 per 100,000 population during 2013-2014 [<a href="#rid45">45</a>]).</p><p class="headingAnchor" id="H21209567"><span class="h3">Children &lt;13 years</span><span class="headingEndMark"> — </span>In children, the first dose of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> is usually administered at age 12 through 15 months and the second dose at age 4 through 6 years [<a href="#rid24">24,46</a>]. A discussion on how to administer the vaccine (eg, choice of vaccine, dose, route) is found below. (See <a class="local">'Administration'</a> below.) </p><p>The minimum age for the first dose is 12 months. Doses administered before age 12 months should not be counted and the child should be revaccinated at 12 through 15 months of age (and ≥3 months after the initial dose) [<a href="#rid36">36</a>]. </p><p>The second dose may be administered earlier than age 4 years (eg, during a varicella outbreak). For children &lt;13 years, the recommended minimum interval between doses is 3 months [<a href="#rid37">37</a>]. However, if the second dose is administered at least 28 days after the first, it need not be repeated [<a href="#rid24">24</a>].</p><p>Children age &lt;13 years who have received &lt;2 doses of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> should receive one or two doses as necessary to be "caught up" [<a href="#rid24">24,46,47</a>]. The schedule does not need to be restarted if the interval between the first and second dose exceeds the recommended interval. </p><p class="headingAnchor" id="H21209874"><span class="h3">Adolescents and adults</span><span class="headingEndMark"> — </span>Adolescents ≥13 years and adults who have not received <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> and have no evidence of chickenpox should receive two doses of single-antigen varicella vaccine, separated by four to eight weeks [<a href="#rid24">24,48,49</a>]. (See <a class="local">'Evidence of immunity'</a> above.) </p><p>A second dose of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> is recommended for adolescents and adults who previously received only one dose [<a href="#rid24">24</a>]. The minimum interval between doses for people ≥13 years is 28 days [<a href="#rid48">48</a>]. </p><p>Our approach to prevaccination serology varies with age:</p><p class="bulletIndent1"><span class="glyph">●</span>We generally do not perform prevaccination serology in adolescents without a history of varicella because they are unlikely to have been exposed to wild-type virus. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We typically perform prevaccination serology in adults born in the United States after 1980. We also perform prevaccination serology in adults born outside the United States (independent of year of birth) because the prevalence in the birth country may not be known. (See <a class="local">'Evidence of immunity'</a> above.) </p><p></p><p class="bulletIndent1">However, previous history of varicella is not a contraindication to <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> and providing vaccine without serologic testing is a reasonable alternative.<strong> </strong></p><p></p><p class="headingAnchor" id="H538416768"><span class="h2">Schedules in other countries</span><span class="headingEndMark"> — </span>Routine schedules for <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> vary from country to country. Schedules for individual countries are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Flisting.html%3Ftopic%3Dvaccine-schedule%26location%3D&amp;token=c1aMGh80n5JfqNiS4zUVhkGZJHzJhW7hYZJMwrVG0LFEFjNX7MxA62uBiY6p7F6hXgl8VfAnRnqUWG6LumPYIJJ9nBP597SAHqgFR7nC42s%3D&amp;TOPIC_ID=8275" target="_blank">World Health Organization</a>.</p><p>The World Health Organization suggests that the first dose of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> be administered at age 12 to 18 months and that the second dose (for countries with a two-dose schedule) be administered at the recommended minimum interval provided by the vaccine manufacturer (ranging from 4 weeks to 3 months) [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H21208215"><span class="h2">Special circumstances</span><span class="headingEndMark"> — </span>The routine immunization schedule may need to be altered in certain circumstances, including: </p><p class="headingAnchor" id="H21208304"><span class="h3">Recent receipt of immune globulin or blood</span><span class="headingEndMark"> — </span>The receipt of parenterally administered <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> or antibody-containing blood products can blunt or block the host response to certain live-virus vaccines (eg, measles). Whether these products affect the antibody response to <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> is not known [<a href="#rid51">51</a>]. However, because of potential inhibition of the immune response, the administration of varicella vaccine should be delayed in people who have received immune globulin or blood products. The suggested interval is the same as that recommended for measles-containing vaccines  (<a class="graphic graphic_table graphicRef72640" href="/d/graphic/72640.html" rel="external">table 1</a>) [<a href="#rid51">51</a>]. </p><p>Postpartum administration of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> to women who received anti-D (Rho) <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> or blood products during the last trimester of pregnancy or at delivery is discussed separately. (See  <a class="medical medical_review" href="/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Postpartum immunization'</a>.)</p><p>If <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> or blood products must be given within 14 days after administration of a varicella-containing vaccine, another dose of the vaccine should be administered after the interval suggested in the table  (<a class="graphic graphic_table graphicRef72640" href="/d/graphic/72640.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H21208461"><span class="h3">Antiviral therapy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">Varicella vaccine</a> virus is susceptible to <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>, and <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a>. These agents should be avoided from 1 day before until 14 days after receipt of varicella vaccine [<a href="#rid52">52</a>]. </p><p class="headingAnchor" id="H21211620"><span class="h3">Salicylate therapy</span><span class="headingEndMark"> — </span>It is not known whether Reye syndrome results from administration of salicylates after varicella immunization. However, because of the association between salicylates, natural varicella, and Reye syndrome, the vaccine manufacturer recommends that salicylates be avoided for at least six weeks after VZV vaccine [<a href="#rid24">24,46</a>]. (See  <a class="medical medical_review" href="/d/html/6154.html" rel="external">"Acute toxic-metabolic encephalopathy in children", section on 'Reye syndrome'</a>.) </p><p class="headingAnchor" id="H195935059"><span class="h1">ADMINISTRATION</span></p><p class="headingAnchor" id="H21209402"><span class="h2">Vaccine formulations</span><span class="headingEndMark"> — </span>Two live, attenuated VZV vaccines are licensed in the United States for the prevention of varicella [<a href="#rid24">24,25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A single-antigen <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> that contains a minimum of 1350 plaque-forming units (PFU) of the Oka strain of VZV and is licensed for use in people age ≥12 months </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A combination measles, mumps, rubella, and <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> (MMRV) that contains a minimum of 9772 PFU of VZV and is licensed for use in people age 12 months through 12 years</p><p></p><p>In other countries, varicella vaccines may contain different amounts of VZV (typically ranging from 1000 to 17,000 PFU) and be licensed for people age ≥9 months [<a href="#rid50">50</a>]. </p><p>Herpes zoster vaccine is discussed separately. (See  <a class="medical medical_review" href="/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)"</a>.)</p><p class="headingAnchor" id="H21208708"><span class="h2">Choice of vaccine</span></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompetent children &lt;13 years may receive either single-antigen <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> or combination measles, mumps, rubella, and varicella vaccine (MMRV).</p><p></p><p class="bulletIndent1">The routine schedule for <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> generally is the same as that for measles, mumps, and rubella vaccine (MMR)  (<a class="graphic graphic_figure graphicRef82617" href="/d/graphic/82617.html" rel="external">figure 2</a>). For children who require both varicella and MMR vaccine, the decision to use MMRV or separate varicella and MMR vaccines should be made on a case-by-case basis after a discussion of the risks and benefits of each strategy with the child's parents or caregivers [<a href="#rid53">53</a>]. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fvpd%2Fmmr%2Fhcp%2Fvacopt-factsheet-hcp.html&amp;token=tF%2FG0g1G66lNQera%2Bj9XUF4fWh%2FlQiyTIeZllJcizjVYAgP%2FeAMLAiLv8mGQqm8r5bb89QNMwj6%2FzrqfAttC5ZODP7s1imVWU7kg3VvM0ds%3D&amp;TOPIC_ID=8275" target="_blank">Centers for Disease Control and Prevention</a> (CDC) provides information and a fact sheet to help explain the options. (See <a class="local">'Local and systemic reactions'</a> below.)</p><p></p><p class="bulletIndent1">If the parents or caregivers do not have a preference:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the <strong>first</strong> doses of varicella and MMR vaccines:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest separate varicella and MMR vaccines for children 12 through 47 months of age (ie, administered at the same visit, but at different sites) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest MMRV for children 48 months through 12 years of age</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the <strong>second</strong> doses of varicella and MMR vaccines in children 15 months through 12 years of age, we suggest MMRV</p><p></p><p class="bulletIndent1">The immunogenicity of MMRV is similar to that when varicella and MMR vaccines are administered at separate injection sites [<a href="#rid54">54</a>]. However, the risk of febrile seizures is increased when MMRV is administered for the first dose in young children. In several large post-licensure studies, administration of MMRV at age 12 to 23 months was associated with an approximately twofold increased risk of febrile seizures one to two weeks after immunization compared with separate injections of varicella and MMR (approximately 1 in 1250 versus 1 in 2500)  (<a class="graphic graphic_table graphicRef65930" href="/d/graphic/65930.html" rel="external">table 2</a>) [<a href="#rid55">55-59</a>]. In another large post-licensure study, neither MMRV nor separate injections of MMR and <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> was associated with an increased risk of febrile seizures at age 4 to 6 years [<a href="#rid60">60</a>]. (See <a class="local">'Local and systemic reactions'</a> below.)</p><p></p><p class="bulletIndent1">Our preferences are consistent with the recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) [<a href="#rid53">53,59,61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children &lt;13 years with HIV infection <strong>without</strong> severe immunosuppression may receive single-antigen <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a>, but should not receive MMRV. (See  <a class="medical medical_review" href="/d/html/3706.html" rel="external">"Immunizations in persons with HIV", section on 'Varicella vaccine'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adolescents and adults should receive single-antigen <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a>. </p><p></p><p class="bulletIndent1">If an adult or adolescent inadvertently receives a dose of the herpes zoster vaccine rather than the varicella zoster vaccine, the dose of zoster vaccine can be counted as one dose of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> [<a href="#rid62">62</a>]. </p><p></p><p class="headingAnchor" id="H21208573"><span class="h2">Dose and route</span><span class="headingEndMark"> — </span>The dose of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> (single-antigen or MMRV) is 0.5 mL. Varicella-containing vaccines are administered subcutaneously or intramuscularly [<a href="#rid54">54,63</a>]. Intramuscular administration results in similar rates of seroconversion [<a href="#rid64">64</a>]. Additional information on vaccine administration is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults", section on 'Administration'</a> and  <a class="medical medical_review" href="/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview", section on 'Vaccine administration'</a>.)</p><p class="headingAnchor" id="H195935066"><span class="h2">Contraindications and precautions</span><span class="headingEndMark"> — </span>Contraindications to administration of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> include  (<a class="graphic graphic_table graphicRef105431" href="/d/graphic/105431.html" rel="external">table 3</a>) [<a href="#rid24">24,25,52,65</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Severe allergic reaction (eg, anaphylaxis) to a previous dose of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> or component of varicella vaccine (eg, <a class="drug drug_general" data-topicid="9686" href="/d/drug information/9686.html" rel="external">neomycin</a>, gelatin); varicella vaccines do not contain egg protein (see  <a class="medical medical_review" href="/d/html/2074.html" rel="external">"Allergic reactions to vaccines"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy or trying to become pregnant; immunization before and after pregnancy is discussed separately (see  <a class="medical medical_review" href="/d/html/442.html" rel="external">"Immunizations during pregnancy"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe</strong> immunosuppression due to: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hematologic and solid tumors or current receipt of chemotherapy (see  <a class="medical medical_review" href="/d/html/3899.html" rel="external">"Immunizations in adults with cancer", section on 'Varicella vaccine'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Congenital or acquired T-lymphocyte immunodeficiency (see  <a class="medical medical_review" href="/d/html/106521.html" rel="external">"Immunizations in patients with inborn errors of immunity", section on 'Live vaccines'</a>)</p><p></p><p class="bulletIndent2">B-lymphocyte (humoral) deficiencies (eg, hypogammaglobulinemia) are not a contraindication to single-antigen <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a>, but the blood products used to treat humoral deficiencies may interfere with the immune response (see <a class="local">'Recent receipt of immune globulin or blood'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HIV infection; HIV-infected patients <strong>without</strong> severe immunosuppression may receive single-antigen <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> (see  <a class="medical medical_review" href="/d/html/3706.html" rel="external">"Immunizations in persons with HIV", section on 'Varicella vaccine'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Current receipt of immunosuppressive agents, such as those administered to patients who have undergone solid organ or hematopoietic stem cell transplant, as well as those receiving biologic agents for autoimmune conditions (eg, IL-1 receptor antagonists [eg, <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a>], tumor necrosis factor-alpha inhibitors [eg, <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>], and anti-CD20 agents [eg, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>]) (see  <a class="medical medical_review" href="/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients", section on 'Varicella'</a> and  <a class="medical medical_review" href="/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients", section on 'Varicella'</a> and  <a class="medical medical_review" href="/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Long-term high-dose systemic glucocorticoid therapy (≥2 weeks of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> ≥20 mg per day or prednisone ≥2 mg/kg per day [for children who weigh &lt;10 kg] or equivalent) </p><p></p><p class="bulletIndent2">Lower dose, topical, or inhaled glucocorticoid therapy is not a contraindication to <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> (see <a class="local">'Immunocompromised hosts'</a> below) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Untreated active tuberculosis [<a href="#rid25">25</a>]</p><p></p><p>Precautions are conditions that may increase the risk of adverse reactions, diminish the immune response, or make it difficult to differentiate between a clinical manifestation of the condition and a vaccine adverse effect (eg, fever, seizure) [<a href="#rid52">52</a>]. When precautions are present, the risks and benefits of immunization (versus postponing the immunization) should be considered on a case-by-case basis. Precautions to administration of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> include  (<a class="graphic graphic_table graphicRef105431" href="/d/graphic/105431.html" rel="external">table 3</a>) [<a href="#rid24">24,25,52,65</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Varicella vaccination should be deferred in patients at risk for congenital or hereditary immunodeficiency (ie, parent or sibling with hereditary immunodeficiency) until the immunocompetence of the potential vaccinee is clinically substantiated or verified with laboratory testing </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Salicylate therapy (see <a class="local">'Salicylate therapy'</a> above) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A personal history of seizure or history of seizures in a sibling or parent is a precaution for the combination measles, mumps, rubella, and <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a>, but <strong>not</strong> for single-antigen varicella vaccine [<a href="#rid52">52</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recent receipt of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> or antibody containing blood products (see <a class="local">'Recent receipt of immune globulin or blood'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Current <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>, or <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a> therapy (see <a class="local">'Antiviral therapy'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate or severe acute illness with or without fever (ie, illness more severe than upper respiratory infection, otitis media, gastroenteritis); immunization may superimpose vaccine adverse effects on the underlying illness; manifestations of the underlying illness may be mistakenly attributed to the vaccine</p><p></p><p class="headingAnchor" id="H21209230"><span class="h2">Administration with other vaccines</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">Varicella vaccine</a> may be administered at the same visit as other vaccines. If varicella vaccine is not administered on the same day as MMR or intranasal <a class="drug drug_general" data-topicid="9056" href="/d/drug information/9056.html" rel="external">live attenuated influenza vaccine</a>, the vaccines should be separated by at least 28 days [<a href="#rid25">25,66</a>].</p><p class="headingAnchor" id="H538417080"><span class="h1">ADVERSE EVENTS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">Varicella vaccine</a> is generally well tolerated [<a href="#rid67">67-69</a>]. Data from the Vaccine Adverse Events Reporting System in the United States suggest that serious events (ie, those resulting in hospitalization, life-threatening illness, permanent disability, or death) are rare (1.3/100,000 doses administered) [<a href="#rid69">69</a>]. Serious adverse events suspected to have been caused by varicella vaccines should be reported to the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Findex.html&amp;token=8m3rK0tzv73hmwLVujPJP%2FVrZTr5LmKIlDf%2BMKp07YKCkZawMmw76Mlq0N%2Fh3R%2BM&amp;TOPIC_ID=8275" target="_blank">Vaccine Adverse Event Reporting System</a> (VAERS). </p><p class="headingAnchor" id="H538418634"><span class="h2">Local and systemic reactions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Injection site reactions</strong> – Approximately 20 percent of children, and 25 percent of adolescents and adults, complain of pain, tenderness, or redness at the injection site [<a href="#rid39">39,46,63,67,70</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rash</strong> – Approximately 1 to 3 percent of patients who receive <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> develop a localized rash consisting of two to five lesions at the injection site, and another 3 to 5 percent develop a generalized varicella-like rash within one month of immunization [<a href="#rid46">46</a>]. Most of the vesicular rashes that occur within the first two weeks after varicella immunization are caused by wild-type VZV [<a href="#rid67">67</a>]. </p><p></p><p class="bulletIndent1">People who develop a rash after <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> should refrain from physical contact with people who are susceptible to varicella, particularly those who are immunocompromised, until the rash has resolved [<a href="#rid46">46,71,72</a>]. (See <a class="local">'Transmission of vaccine virus'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever and febrile seizures</strong> – Temperature &gt;38.9ºC (102ºF) occurs in approximately 15 percent of children younger than 13 years and temperature &gt;37.8ºC (100ºF) occurs in approximately 10 percent of adolescents and adults [<a href="#rid63">63</a>]. </p><p></p><p class="bulletIndent1">The risk of febrile seizure one to two weeks after separate administration of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> and MMR is approximately 1 in 2500 [<a href="#rid58">58,59</a>]. The risk is increased approximately twofold (ie, 1 in 1250) when combination MMRV is administered to children age 12 to 23 months [<a href="#rid55">55,56</a>]. Neither MMRV nor separate injections of MMR and varicella vaccine appear to be associated with an increased risk of febrile seizures at age 4 to 6 years [<a href="#rid60">60</a>]. (See <a class="local">'Choice of vaccine'</a> above.)</p><p></p><p class="headingAnchor" id="H538417225"><span class="h2">Disseminated vaccine virus</span><span class="headingEndMark"> — </span>Rarely, patients can develop disseminated varicella, meningitis, or encephalitis from vaccine virus [<a href="#rid69">69</a>]. Case reports have identified disseminated disease in immunocompetent, as well as immunocompromised, patients [<a href="#rid67">67,73-76</a>]. To minimize the risk of disseminated disease, vaccination is contraindicated in individuals who are receiving immunosuppressive therapy or have primary or acquired immunodeficiencies. (See <a class="local">'Contraindications and precautions'</a> above and <a class="local">'Immunocompromised hosts'</a> below.) </p><p class="headingAnchor" id="H538417518"><span class="h2">Transmission of vaccine virus</span><span class="headingEndMark"> — </span>Transmission of vaccine virus from a healthy patient to a susceptible contact is rare and is mostly described in case reports [<a href="#rid67">67,70,77-81</a>]. A systematic review of observational studies identified only 13 cases of transmission of vaccine virus from 11 immunocompetent <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> recipients [<a href="#rid82">82</a>]. All but two of the transmissions occurred in household contacts. A subsequent case report described extensive varicella disease in a neonate following maternal postpartum immunization [<a href="#rid83">83</a>]. Although all of the vaccine recipients in the systematic review and in the subsequently published case had a varicella-like or zoster-like rash, postmarketing surveillance suggests that transmission of vaccine virus, including disseminated disease, may occur without a rash [<a href="#rid63">63,81</a>].</p><p>Transmission of vaccine virus from an immunocompromised host to a susceptible contact appears to be more likely. As an example, in one study, transmission of vaccine virus occurred in 17 percent of 88 susceptible siblings of children with leukemia who developed a rash after varicella immunization [<a href="#rid84">84</a>].</p><p>Whenever possible, <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> recipients should avoid close contact with people who are susceptible to varicella and at increased risk for severe disease (eg, those who are immunocompromised, pregnant women, newborn infants of susceptible pregnant women) [<a href="#rid63">63</a>]. The prescribing information suggests avoidance of close contact for up to six weeks, although the optimal duration is uncertain. In the systematic review, among the index cases with varicella-like rash, the rash developed within 12 to 24 days of vaccination [<a href="#rid82">82</a>]. Those who develop a rash after varicella vaccine should refrain from physical contact with people who are susceptible to varicella, particularly those at increased risk of severe infection, until the rash has resolved [<a href="#rid46">46,71,72</a>]. Although secondary cases of vaccine associated varicella are expected to be mild, decisions regarding administration of post-exposure prophylaxis (eg, varicella vaccine or <a class="drug drug_general" data-topicid="9442" href="/d/drug information/9442.html" rel="external">varicella-zoster immune globulin</a>) are individualized according to the level of immune suppression [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/8273.html" rel="external">"Post-exposure prophylaxis against varicella-zoster virus infection"</a>.)</p><p class="headingAnchor" id="H538417308"><span class="h2">Risk of vaccine-associated zoster</span><span class="headingEndMark"> — </span>Immunocompromised patients who receive the <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> are at risk for developing severe and/or disseminated herpes zoster infection with the vaccine strain of the virus [<a href="#rid73">73,85</a>]. Severe vaccine-associated herpes zoster also has been reported in immunocompetent children [<a href="#rid86">86,87</a>]. In such patients, zoster can develop months after vaccination. Wild-type VZV also has been identified in persons with herpes zoster after immunization, indicating that herpes zoster in immunized persons also may result from antecedent natural varicella infection [<a href="#rid88">88</a>]. The impact of varicella vaccination on the incidence of herpes zoster is discussed separately. (See  <a class="medical medical_review" href="/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster"</a>.)</p><p class="headingAnchor" id="H21209041"><span class="h1">POST-VACCINATION SEROLOGY</span><span class="headingEndMark"> — </span>Post-vaccination serology is not recommended for any recipients of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a>, including health care personnel. Commercially available antibody assays are not sensitive enough to reliably detect vaccine-induced antibody, which may result in false negative results and unnecessary revaccination [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H195934807"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H7"><span class="h2">Pregnant women</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">Varicella vaccine</a> is contraindicated in women who are pregnant or are trying to become pregnant. Prevention of varicella during pregnancy and varicella immunization before or after pregnancy are discussed separately. (See  <a class="medical medical_review" href="/d/html/8331.html" rel="external">"Varicella-zoster virus infection in pregnancy", section on 'Post-exposure prophylaxis'</a> and  <a class="medical medical_review" href="/d/html/8331.html" rel="external">"Varicella-zoster virus infection in pregnancy", section on 'Pre-exposure prophylaxis'</a> and  <a class="medical medical_review" href="/d/html/442.html" rel="external">"Immunizations during pregnancy"</a>.) </p><p class="headingAnchor" id="H8"><span class="h2">Immunocompromised hosts</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">Varicella vaccine</a> is a live attenuated vaccine. It is contraindicated in people with severe immunosuppression  (<a class="graphic graphic_table graphicRef105431" href="/d/graphic/105431.html" rel="external">table 3</a>) [<a href="#rid24">24,65,89,90</a>]. (See <a class="local">'Contraindications and precautions'</a> above.)</p><p>However, <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> may be beneficial for certain immunocompromised hosts who are not highly immunocompromised, as described below [<a href="#rid91">91</a>]. Immunization of these patients should only be undertaken with expert guidance and consultation [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/106521.html" rel="external">"Immunizations in patients with inborn errors of immunity", section on 'Live vaccines'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children with leukemia </strong>– Varicella immunization may be suitable for certain children with leukemia who are in remission. Varicella vaccination for children with acute lymphocytic leukemia is discussed separately. (See  <a class="medical medical_review" href="/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'Follow-up'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HIV-infected patients</strong> – Varicella immunization may be administered to HIV-infected adults and children without evidence of severe immunodeficiency. Specific information regarding administration of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> in patients with HIV infection is found elsewhere. (See  <a class="medical medical_review" href="/d/html/3706.html" rel="external">"Immunizations in persons with HIV", section on 'Varicella vaccine'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with T cell abnormalities</strong> – Varicella vaccination may be suitable for certain patients with partial congenital or acquired T-lymphocyte defects who are not severely immunosuppressed. (See  <a class="medical medical_review" href="/d/html/106521.html" rel="external">"Immunizations in patients with inborn errors of immunity", section on 'Live vaccines'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid recipients</strong> – Patients who have received high doses of systemic glucocorticoids (ie, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> ≥20 mg per day or prednisone ≥2 mg/kg per day [for children who weigh &lt;10 kg] or equivalent) may receive <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> after glucocorticoids have been discontinued. The recommended interval between discontinuation of high-dose systemic glucocorticoids and varicella vaccination depends upon the duration of glucocorticoid therapy [<a href="#rid92">92</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If glucocorticoids have been administered for &lt;14 days, varicella vaccination can be administered immediately after discontinuation of treatment, although some experts would delay immunization until two weeks after discontinuation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If glucocorticoids have been administered for ≥14 days, the recommended interval between discontinuation of treatment and varicella vaccination is four weeks</p><p></p><p class="bulletIndent1">Low dose daily or alternate day systemic glucocorticoids (ie, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> &lt;20 mg per day or prednisone &lt;2 mg/kg per day [for children who weigh &lt;10 kg] or equivalent), topical, replacement, and aerosolized glucocorticoids are not a contraindication to <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H87264080"><span class="h2">Contacts of immunocompromised hosts</span><span class="headingEndMark"> — </span>Healthy household contacts of immunocompromised patients should be given <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> to prevent acquisition of wild-type VZV and subsequent transmission to the immunocompromised contact [<a href="#rid24">24,46,65,93-95</a>]. Prelicensure trials and postmarketing surveillance indicate that transmission of vaccine virus from healthy people to susceptible contacts is rare [<a href="#rid67">67,70,77-80,84</a>]. </p><p>If the vaccine recipient develops vesicular skin lesions after vaccination, physical contact with immunocompromised individuals should be avoided until the rash resolves [<a href="#rid24">24,46,71,72</a>]. (See <a class="local">'Transmission of vaccine virus'</a> above.)</p><p class="headingAnchor" id="H87266144"><span class="h2">Health care providers</span><span class="headingEndMark"> — </span>Health care providers should be screened for varicella immunity at the time of employment. Those who lack evidence of immunity and do not have a contraindication to immunization should be immunized. Varicella immunization for health care providers is discussed separately. (See  <a class="medical medical_review" href="/d/html/3889.html" rel="external">"Immunizations for health care providers", section on 'Varicella vaccine'</a> and  <a class="medical medical_review" href="/d/html/4047.html" rel="external">"Prevention and control of varicella-zoster virus in hospitals", section on 'Prevention of varicella among health care personnel'</a>.) </p><p class="headingAnchor" id="H538417383"><span class="h1">POST-EXPOSURE PROPHYLAXIS</span><span class="headingEndMark"> — </span>The use of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> for post-exposure prophylaxis is discussed separately. (See  <a class="medical medical_review" href="/d/html/8273.html" rel="external">"Post-exposure prophylaxis against varicella-zoster virus infection", section on 'Who is eligible?'</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">BREAKTHROUGH VARICELLA</span><span class="headingEndMark"> — </span>"Breakthrough varicella" or "mild varicella-like syndrome" (MVLS) refers to infection after exposure to wild-type virus in those who have been previously vaccinated. Most studies have noted MVLS occurring in &lt;1 to 3 percent of vaccinated children each year after vaccination [<a href="#rid96">96-98</a>]. Most documented cases of varicella in vaccinated children are mild [<a href="#rid99">99</a>]. Fever is often absent; the rash may be maculopapular rather than vesicular, with &lt;50 lesions (compared with a median of 300 in unvaccinated children) [<a href="#rid96">96-98</a>]. However, children with breakthrough infection can still transmit varicella virus to other children [<a href="#rid3">3,100</a>]. (See  <a class="medical medical_review" href="/d/html/8284.html" rel="external">"Clinical features of varicella-zoster virus infection: Chickenpox", section on 'Impact of vaccine on clinical manifestations'</a>.)</p><p>Breakthrough varicella may arise from primary or secondary vaccine failure. "Primary vaccine failure" refers to the failure to mount a protective immune response to a dose of vaccine; "secondary vaccine failure" refers to the gradual loss of immunity after initial vaccine response (ie, waning immunity). Primary vaccine failure after a single dose may occur in as many as one-quarter of patients. As an example, in an observational study in which varicella antibody was assessed with a research assay (fluorescent antibody to membrane antigen), which is more sensitive than commercially available varicella antibody assays, primary vaccine failure occurred in 24 percent of 148 children [<a href="#rid35">35</a>]. Primary vaccine failure occurs in &lt;1 percent of people who receive two doses [<a href="#rid24">24,48,101,102</a>]. Studies evaluating secondary vaccine failure after a single dose of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> have inconsistent results [<a href="#rid42">42,103-105</a>]. </p><p class="headingAnchor" id="H4184990844"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110219.html" rel="external">"Society guideline links: Varicella-zoster virus"</a> and  <a class="medical medical_society_guidelines" href="/d/html/109228.html" rel="external">"Society guideline links: Immunizations in children and adolescents"</a>.)</p><p class="headingAnchor" id="H34"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15741.html" rel="external">"Patient education: Vaccines for babies and children age 0 to 6 years (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15375.html" rel="external">"Patient education: Chickenpox (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1214.html" rel="external">"Patient education: Why does my child need vaccines? (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1216.html" rel="external">"Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/3997.html" rel="external">"Patient education: Chickenpox prevention and treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H35"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefits of immunization</strong> – Routine immunization with two doses of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> is at least 90 percent effective in preventing primary varicella infection and 99 percent effective in preventing severe varicella disease. It also reduces the risk of transmission and varicella-related health care utilization. (See <a class="local">'Benefits of immunization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence of immunity</strong> – Evidence of immunity includes documentation of age-appropriate immunization; laboratory evidence of immunity or laboratory confirmation of disease; diagnosis or verification of typical primary varicella infection by a health care provider; or, for people born in the United States, birth before 1980 unless they are immunosuppressed, pregnant, or a health care worker. (See <a class="local">'Evidence of immunity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to immunization in the United States</strong> – In the United States, we recommend varicella immunization for children ≥12 months of age, adolescents, and adults without evidence of immunity, as recommended by the Advisory Committee on Immunization Practices (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). Two doses of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> are administered to reduce the risk of breakthrough varicella:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In children, the two doses are typically administered at age 12 through 15 months and at age 4 through 6 years. (See <a class="local">'Children &lt;13 years'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In adolescents ≥13 years and adults, the two doses are usually separated by 4 to 8 weeks. (See <a class="local">'Adolescents and adults'</a> above.)</p><p></p><p class="bulletIndent1">Children ≥4 years, adolescents, and adults who have received only one dose of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> should receive a "catch-up" dose. (See <a class="local">'Schedules in the United States'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to immunization in other countries</strong> – Routine schedules for <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> vary from country to country. Schedules for individual countries are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Flisting.html%3Ftopic%3Dvaccine-schedule%26location%3D&amp;token=c1aMGh80n5JfqNiS4zUVhkGZJHzJhW7hYZJMwrVG0LFEFjNX7MxA62uBiY6p7F6hXgl8VfAnRnqUWG6LumPYIJJ9nBP597SAHqgFR7nC42s%3D&amp;TOPIC_ID=8275" target="_blank">World Health Organization</a>. (See <a class="local">'Schedules in other countries'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Priority groups</strong> – Varicella immunization is particularly important for health care providers, contacts of immunocompromised hosts, and other individuals at high risk of exposure or transmission (eg, teachers of young children, military personnel, etc). (See <a class="local">'Priority groups'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications and precautions</strong> – Contraindications to <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> include severe allergic reaction to a previous dose or vaccine component (eg, gelatin, <a class="drug drug_general" data-topicid="9686" href="/d/drug information/9686.html" rel="external">neomycin</a>), pregnancy, and being severely immunocompromised  (<a class="graphic graphic_table graphicRef105431" href="/d/graphic/105431.html" rel="external">table 3</a>). (See <a class="local">'Contraindications and precautions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The dose of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> (single-antigen varicella vaccine or combination measles, mumps, rubella, and varicella vaccine) is 0.5 mL. Varicella-containing vaccines are administered subcutaneously, usually in the upper outer triceps. Varicella vaccine may be administered at the same visit as other vaccines. If varicella vaccine is not administered on the same day as measles, mumps, and rubella vaccine, the two vaccines should be separated by at least 28 days. (See <a class="local">'Administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">Varicella vaccine</a> is generally well tolerated; local injection reactions, rash, and febrile seizures have been reported. (See <a class="local">'Local and systemic reactions'</a> above.)</p><p></p><p class="bulletIndent1">Transmission of vaccine virus is rare and generally occurs in the context of a varicella-type rash. People who develop a rash after <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> should refrain from physical contact with people who are susceptible to varicella, particularly those who are immunocompromised, until the rash has resolved. Whenever possible, varicella vaccine recipients should avoid close contact with people who are susceptible to varicella and at increased risk for severe disease. (See <a class="local">'Transmission of vaccine virus'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Seward JF, Marin M, Vázquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis 2008; 197 Suppl 2:S82.</a></li><li><a class="nounderline abstract_t">Vázquez M, LaRussa PS, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344:955.</a></li><li><a class="nounderline abstract_t">Seward JF, Zhang JX, Maupin TJ, et al. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA 2004; 292:704.</a></li><li><a class="nounderline abstract_t">Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991; 9:643.</a></li><li><a class="nounderline abstract_t">Sadzot-Delvaux C, Rentier B, Wutzler P, et al. Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis 2008; 197 Suppl 2:S185.</a></li><li><a class="nounderline abstract_t">Macartney KK, Burgess MA. Varicella vaccination in Australia and New Zealand. J Infect Dis 2008; 197 Suppl 2:S191.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Evolution of varicella surveillance--selected states, 2000-2010. MMWR Morb Mortal Wkly Rep 2012; 61:609.</a></li><li><a class="nounderline abstract_t">Marin M, Zhang JX, Seward JF. Near elimination of varicella deaths in the US after implementation of the vaccination program. Pediatrics 2011; 128:214.</a></li><li><a class="nounderline abstract_t">Lee BR, Feaver SL, Miller CA, et al. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis 2004; 190:477.</a></li><li><a class="nounderline abstract_t">Perella D, Wang C, Civen R, et al. Varicella Vaccine Effectiveness in Preventing Community Transmission in the 2-Dose Era. Pediatrics 2016; 137.</a></li><li><a class="nounderline abstract_t">Streng A, Grote V, Rack-Hoch A, Liese JG. Decline of Neurologic Varicella Complications in Children During the First Seven Years After Introduction of Universal Varicella Vaccination in Germany, 2005-2011. Pediatr Infect Dis J 2017; 36:79.</a></li><li><a class="nounderline abstract_t">Di Pietrantonj C, Rivetti A, Marchione P, et al. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev 2020; 4:CD004407.</a></li><li><a class="nounderline abstract_t">Marin M, Lopez AS, Melgar M, et al. Decline in Severe Varicella Disease During the United States Varicella Vaccination Program: Hospitalizations and Deaths, 1990-2019. J Infect Dis 2022; 226:S407.</a></li><li><a class="nounderline abstract_t">Weinmann S, Naleway AL, Koppolu P, et al. Incidence of Herpes Zoster Among Children: 2003-2014. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Harpaz R, Leung JW. The Epidemiology of Herpes Zoster in the United States During the Era of Varicella and Herpes Zoster Vaccines: Changing Patterns Among Children. Clin Infect Dis 2019; 69:345.</a></li><li><a class="nounderline abstract_t">Rafferty E, Reifferscheid L, Russell ML, et al. The impact of varicella vaccination on paediatric herpes zoster epidemiology: a Canadian population-based retrospective cohort study. Eur J Clin Microbiol Infect Dis 2021; 40:2363.</a></li><li><a class="nounderline abstract_t">Marin M, Watson TL, Chaves SS, et al. Varicella among adults: data from an active surveillance project, 1995-2005. J Infect Dis 2008; 197 Suppl 2:S94.</a></li><li><a class="nounderline abstract_t">Chaves SS, Lopez AS, Watson TL, et al. Varicella in infants after implementation of the US varicella vaccination program. Pediatrics 2011; 128:1071.</a></li><li><a class="nounderline abstract_t">Waye A, Jacobs P, Tan B. The impact of the universal infant varicella immunization strategy on Canadian varicella-related hospitalization rates. Vaccine 2013; 31:4744.</a></li><li class="breakAll">World Health Organization. Systematic review of available evidence on effectiveness and duration of protection of varicella vaccines. April 2014. http://www.who.int/immunization/sage/meetings/2014/april/presentations_background_docs/en/ (Accessed on October 20, 2015).</li><li><a class="nounderline abstract_t">Marin M, Marti M, Kambhampati A, et al. Global Varicella Vaccine Effectiveness: A Meta-analysis. Pediatrics 2016; 137:e20153741.</a></li><li><a class="nounderline abstract_t">Marin M, Leung J, Anderson TC, Lopez AS. Monitoring Varicella Vaccine Impact on Varicella Incidence in the United States: Surveillance Challenges and Changing Epidemiology, 1995-2019. J Infect Dis 2022; 226:S392.</a></li><li><a class="nounderline abstract_t">Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 2003; 112:e98.</a></li><li><a class="nounderline abstract_t">Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Varicella. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 14th ed, Hall E, Wodi AP, Hamborsky J, et al (Eds). Public Health Foundation, Washington, DC 2021 http://www.cdc.gov/vaccines/pubs/pinkbook/index.html (Accessed on February 21, 2022).</li><li><a class="nounderline abstract_t">Lee GM. Varicella vaccination in adults: is it cost-effective? Clin Infect Dis 2007; 44:1049.</a></li><li><a class="nounderline abstract_t">Kjersem H, Jepsen S. Varicella among immigrants from the tropics, a health problem. Scand J Soc Med 1990; 18:171.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Varicella outbreaks among Mexican adults--Alabama, 2000. MMWR Morb Mortal Wkly Rep 2000; 49:735.</a></li><li><a class="nounderline abstract_t">Merrett P, Schwartzman K, Rivest P, Greenaway C. Strategies to prevent varicella among newly arrived adult immigrants and refugees: a cost-effectiveness analysis. Clin Infect Dis 2007; 44:1040.</a></li><li><a class="nounderline abstract_t">Wodi AP, Murthy N, McNally V, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:137.</a></li><li><a class="nounderline abstract_t">Murthy N, Wodi AP, McNally V, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:141.</a></li><li><a class="nounderline abstract_t">Lopez AS, Guris D, Zimmerman L, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics 2006; 117:e1070.</a></li><li><a class="nounderline abstract_t">Bayer O, Heininger U, Heiligensetzer C, von Kries R. Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine 2007; 25:6655.</a></li><li><a class="nounderline abstract_t">Tugwell BD, Lee LE, Gillette H, et al. Chickenpox outbreak in a highly vaccinated school population. Pediatrics 2004; 113:455.</a></li><li><a class="nounderline abstract_t">Michalik DE, Steinberg SP, Larussa PS, et al. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis 2008; 197:944.</a></li><li class="breakAll">Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Timing ans spacing of immunobiologics. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html (Accessed on February 19, 2022).</li><li><a class="nounderline abstract_t">Ngai AL, Staehle BO, Kuter BJ, et al. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J 1996; 15:49.</a></li><li><a class="nounderline abstract_t">Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004; 23:132.</a></li><li><a class="nounderline abstract_t">Prymula R, Bergsaker MR, Esposito S, et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet 2014; 383:1313.</a></li><li><a class="nounderline abstract_t">Shapiro ED, Vazquez M, Esposito D, et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 2011; 203:312.</a></li><li><a class="nounderline abstract_t">Leung J, Lopez AS, Blostein J, et al. Impact of the US Two-dose Varicella Vaccination Program on the Epidemiology of Varicella Outbreaks: Data from Nine States, 2005-2012. Pediatr Infect Dis J 2015; 34:1105.</a></li><li><a class="nounderline abstract_t">Baxter R, Ray P, Tran TN, et al. Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study. Pediatrics 2013; 131:e1389.</a></li><li><a class="nounderline abstract_t">Siedler A, Rieck T, Tolksdorf K. Strong Additional Effect of a Second Varicella Vaccine Dose in Children in Germany, 2009-2014. J Pediatr 2016; 173:202.</a></li><li><a class="nounderline abstract_t">Leung J, Harpaz R. Impact of the Maturing Varicella Vaccination Program on Varicella and Related Outcomes in the United States: 1994-2012. J Pediatric Infect Dis Soc 2016; 5:395.</a></li><li><a class="nounderline abstract_t">Lopez AS, Zhang J, Marin M. Epidemiology of Varicella During the 2-Dose Varicella Vaccination Program - United States, 2005-2014. MMWR Morb Mortal Wkly Rep 2016; 65:902.</a></li><li class="breakAll">American Academy of Pediatrics. Varicella-zoster virus infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca IL 2021. p.831.</li><li><a class="nounderline abstract_t">Marin M, Nguyen HQ, Keen J, et al. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003. Pediatrics 2005; 115:900.</a></li><li><a class="nounderline abstract_t">Kuter BJ, Ngai A, Patterson CM, et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine 1995; 13:967.</a></li><li><a class="nounderline abstract_t">Freedman MS, Bernstein H, Ault KA, Advisory Committee on Immunization Practices. Recommended Adult Immunization Schedule, United States, 2021. Ann Intern Med 2021; 174:374.</a></li><li><a class="nounderline abstract_t">Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec 2014; 89:265.</a></li><li class="breakAll">American Academy of Pediatrics. Active immunization after receipt of immune globulin or other blood products. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.40.</li><li class="breakAll">Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Contraindications and precautions. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html (Accessed on February 19, 2022).</li><li><a class="nounderline abstract_t">McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</a></li><li class="breakAll">ProQuad (measles, mumps, rubella, and varicella virus vaccine). US Food and Drug Administration approved product information. Revised February, 2023. Available online at: https://www.fda.gov/media/147562/download (Accessed on March 02, 2023).</li><li><a class="nounderline abstract_t">Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009; 27:4656.</a></li><li><a class="nounderline abstract_t">Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010; 126:e1.</a></li><li><a class="nounderline abstract_t">MacDonald SE, Dover DC, Simmonds KA, Svenson LW. Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ 2014; 186:824.</a></li><li><a class="nounderline abstract_t">Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep 2008; 57:258.</a></li><li><a class="nounderline abstract_t">Klein NP, Lewis E, Baxter R, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics 2012; 129:809.</a></li><li><a class="nounderline abstract_t">Committee on Infectious Diseases. Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics 2011; 128:630.</a></li><li class="breakAll">Immunzation Action Coalition. Ask the experts: Varicella. http://www.immunize.org/askexperts/experts_var.asp (Accessed on October 21, 2015).</li><li class="breakAll">Varivax (varicella virus vaccine). US Food and Drug Administration approved product information. Revised February, 2023. Available online at: https://www.fda.gov/media/76008/download (Accessed on March 02, 2023).</li><li><a class="nounderline abstract_t">Dennehy PH, Reisinger KS, Blatter MM, Veloudis BA. Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children. Pediatrics 1991; 88:604.</a></li><li><a class="nounderline abstract_t">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Simultaneous administration of varicella vaccine and other recommended childhood vaccines--United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2001; 50:1058.</a></li><li><a class="nounderline abstract_t">Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis 2008; 197 Suppl 2:S165.</a></li><li><a class="nounderline abstract_t">Su JR, Leroy Z, Lewis PW, et al. Safety of Second-Dose Single-Antigen Varicella Vaccine. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Moro PL, Leung J, Marquez P, et al. Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020. J Infect Dis 2022; 226:S431.</a></li><li><a class="nounderline abstract_t">Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med 1984; 310:1409.</a></li><li><a class="nounderline abstract_t">Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.</a></li><li><a class="nounderline abstract_t">Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol 2007; 28:702.</a></li><li><a class="nounderline abstract_t">Bhalla P, Forrest GN, Gershon M, et al. Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation. Clin Infect Dis 2015; 60:1068.</a></li><li><a class="nounderline abstract_t">Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev 2013; 26:728.</a></li><li><a class="nounderline abstract_t">Levin MJ, DeBiasi RL, Bostik V, Schmid DS. Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine. J Infect Dis 2008; 198:1444.</a></li><li><a class="nounderline abstract_t">Harrington WE, Mató S, Burroughs L, et al. Vaccine Oka Varicella Meningitis in Two Adolescents. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Salzman MB, Sharrar RG, Steinberg S, LaRussa P. Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr 1997; 131:151.</a></li><li><a class="nounderline abstract_t">LaRussa P, Steinberg S, Meurice F, Gershon A. Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts. J Infect Dis 1997; 176:1072.</a></li><li><a class="nounderline abstract_t">Diaz PS, Au D, Smith S, et al. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics 1991; 87:166.</a></li><li><a class="nounderline abstract_t">Grossberg R, Harpaz R, Rubtcova E, et al. Secondary transmission of varicella vaccine virus in a chronic care facility for children. J Pediatr 2006; 148:842.</a></li><li><a class="nounderline abstract_t">Woodward M, Marko A, Galea S, et al. Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data. Open Forum Infect Dis 2019; 6.</a></li><li><a class="nounderline abstract_t">Marin M, Leung J, Gershon AA. Transmission of Vaccine-Strain Varicella-Zoster Virus: A Systematic Review. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Saringkarisate K, Len KA, Melish ME, et al. Vaccine-Strain Varicella Virus Transmitted to a Term Infant Following Maternal Postpartum Vaccination. J Pediatric Infect Dis Soc 2022; 11:452.</a></li><li><a class="nounderline abstract_t">Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr 1990; 116:184.</a></li><li><a class="nounderline abstract_t">Gonzales JA, Levison AL, Stewart JM, et al. Retinal necrosis following varicella-zoster vaccination. Arch Ophthalmol 2012; 130:1355.</a></li><li><a class="nounderline abstract_t">Moodley A, Swanson J, Grose C, Bonthius DJ. Severe Herpes Zoster Following Varicella Vaccination in Immunocompetent Young Children. J Child Neurol 2019; 34:184.</a></li><li><a class="nounderline abstract_t">Chun C, Weinmann S, Riedlinger K, et al. Laboratory characteristics of suspected herpes zoster in vaccinated children. Pediatr Infect Dis J 2011; 30:719.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update. Pediatrics 2000; 105:136.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Varicella-related deaths among adults--United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:409.</a></li><li><a class="nounderline abstract_t">Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999; 130:922.</a></li><li><a class="nounderline abstract_t">Levin MJ. Varicella vaccination of immunocompromised children. J Infect Dis 2008; 197 Suppl 2:S200.</a></li><li class="breakAll">American Academy of Pediatrics. Immunization and other considerations in immunocompromised children. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.72.</li><li><a class="nounderline abstract_t">Kappagoda C, Shaw P, Burgess M, et al. Varicella vaccine in non-immune household contacts of children with cancer or leukaemia. J Paediatr Child Health 1999; 35:341.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Notes from the field: severe varicella in an immunocompromised child exposed to an unvaccinated sibling with varicella--Minnesota, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:541.</a></li><li class="breakAll">Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993; 91:17.</a></li><li><a class="nounderline abstract_t">White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992; 11:19.</a></li><li><a class="nounderline abstract_t">Clements DA. Modified varicella-like syndrome. Infect Dis Clin North Am 1996; 10:617.</a></li><li><a class="nounderline abstract_t">Gould PL, Leung J, Scott C, et al. An outbreak of varicella in elementary school children with two-dose varicella vaccine recipients--Arkansas, 2006. Pediatr Infect Dis J 2009; 28:678.</a></li><li><a class="nounderline abstract_t">Shapiro ED. Second dose of varicella vaccine for children: are we giving it too late? J Infect Dis 2008; 197:935.</a></li><li><a class="nounderline abstract_t">Gershon AA, Steinberg SP, LaRussa P, et al. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988; 158:132.</a></li><li><a class="nounderline abstract_t">Wallace MR, Bowler WA, Murray NB, et al. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117:358.</a></li><li><a class="nounderline abstract_t">Black S, Ray P, Shinefield H, et al. Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program. J Infect Dis 2008; 197 Suppl 2:S139.</a></li><li><a class="nounderline abstract_t">Vázquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA 2004; 291:851.</a></li><li><a class="nounderline abstract_t">Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007; 356:1121.</a></li></ol></div><div id="topicVersionRevision">Topic 8275 Version 63.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419415" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Varicella vaccine effectiveness in the US vaccination program: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11274621" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The effectiveness of the varicella vaccine in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304467" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Contagiousness of varicella in vaccinated cases: a household contact study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1659052" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419395" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Varicella vaccination in Japan, South Korea, and Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419396" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Varicella vaccination in Australia and New Zealand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22895384" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evolution of varicella surveillance--selected states, 2000-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21788222" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Near elimination of varicella deaths in the US after implementation of the vaccination program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15243919" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : An elementary school outbreak of varicella attributed to vaccine failure: policy implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26977081" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Varicella Vaccine Effectiveness in Preventing Community Transmission in the 2-Dose Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27749651" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Decline of Neurologic Varicella Complications in Children During the First Seven Years After Introduction of Universal Varicella Vaccination in Germany, 2005-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32309885" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Vaccines for measles, mumps, rubella, and varicella in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36265852" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Decline in Severe Varicella Disease During the United States Varicella Vaccination Program: Hospitalizations and Deaths, 1990-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31182552" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Incidence of Herpes Zoster Among Children: 2003-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30496366" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Epidemiology of Herpes Zoster in the United States During the Era of Varicella and Herpes Zoster Vaccines: Changing Patterns Among Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34175998" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The impact of varicella vaccination on paediatric herpes zoster epidemiology: a Canadian population-based retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419417" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Varicella among adults: data from an active surveillance project, 1995-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123875" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Varicella in infants after implementation of the US varicella vaccination program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23973325" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The impact of the universal infant varicella immunization strategy on Canadian varicella-related hospitalization rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23973325" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The impact of the universal infant varicella immunization strategy on Canadian varicella-related hospitalization rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908671" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Global Varicella Vaccine Effectiveness: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36265855" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Monitoring Varicella Vaccine Impact on Varicella Incidence in the United States: Surveillance Challenges and Changing Epidemiology, 1995-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12897314" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17585291" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17585291" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17366447" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Varicella vaccination in adults: is it cost-effective?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2237323" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Varicella among immigrants from the tropics, a health problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11411828" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Varicella outbreaks among Mexican adults--Alabama, 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17366446" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Strategies to prevent varicella among newly arrived adult immigrants and refugees: a cost-effectiveness analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36757872" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36757861" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740809" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17706845" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Metaanalysis of vaccine effectiveness in varicella outbreaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993534" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Chickenpox outbreak in a highly vaccinated school population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419532" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Primary vaccine failure after 1 dose of varicella vaccine in healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419532" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary vaccine failure after 1 dose of varicella vaccine in healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8684876" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14872179" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Ten year follow-up of healthy children who received one or two injections of varicella vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24485548" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208922" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effectiveness of 2 doses of varicella vaccine in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26186103" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Impact of the US Two-dose Varicella Vaccination Program on the Epidemiology of Varicella Outbreaks: Data from Nine States, 2005-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23545380" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26995703" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Strong Additional Effect of a Second Varicella Vaccine Dose in Children in Germany, 2009-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26407276" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Impact of the Maturing Varicella Vaccination Program on Varicella and Related Outcomes in the United States: 1994-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27584717" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Epidemiology of Varicella During the 2-Dose Varicella Vaccination Program - United States, 2005-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27584717" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Epidemiology of Varicella During the 2-Dose Varicella Vaccination Program - United States, 2005-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15805362" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8525689" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33571011" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Recommended Adult Immunization Schedule, United States, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24983077" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Varicella and herpes zoster vaccines: WHO position paper, June 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24983077" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Varicella and herpes zoster vaccines: WHO position paper, June 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24983077" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Varicella and herpes zoster vaccines: WHO position paper, June 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23760231" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23760231" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19520201" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20587679" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24914115" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20448530" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18340332" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473362" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Measles-containing vaccines and febrile seizures in children age 4 to 6 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21873692" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21873692" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21873692" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1881743" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11808928" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Simultaneous administration of varicella vaccine and other recommended childhood vaccines--United States, 1995-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419392" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The safety profile of varicella vaccine: a 10-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28174201" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Safety of Second-Dose Single-Antigen Varicella Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36265846" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6325909" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Live attenuated varicella virus vaccine. Efficacy trial in healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22108587" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17520544" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25452596" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092852" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pathogenesis and current approaches to control of varicella-zoster virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18826373" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31776194" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Vaccine Oka Varicella Meningitis in Two Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9255208" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9333170" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846236" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769402" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Secondary transmission of varicella vaccine virus in a chronic care facility for children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31392326" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31471448" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Transmission of Vaccine-Strain Varicella-Zoster Virus: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35751631" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Vaccine-Strain Varicella Virus Transmitted to a Term Infant Following Maternal Postpartum Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2153790" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23044970" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Retinal necrosis following varicella-zoster vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30628536" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Severe Herpes Zoster Following Varicella Vaccination in Immunocompetent Young Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21346684" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Laboratory characteristics of suspected herpes zoster in vaccinated children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10617719" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9162840" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Varicella-related deaths among adults--United States, 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10375341" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Recent advances in varicella-zoster virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419398" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Varicella vaccination of immunocompromised children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419398" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Varicella vaccination of immunocompromised children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10457288" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Varicella vaccine in non-immune household contacts of children with cancer or leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22810269" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Notes from the field: severe varicella in an immunocompromised child exposed to an unvaccinated sibling with varicella--Minnesota, 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22810269" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Notes from the field: severe varicella in an immunocompromised child exposed to an unvaccinated sibling with varicella--Minnesota, 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416499" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Modified chickenpox in children immunized with the Oka/Merck varicella vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1312704" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8856356" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Modified varicella-like syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19593254" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : An outbreak of varicella in elementary school children with two-dose varicella vaccine recipients--Arkansas, 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419530" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Second dose of varicella vaccine for children: are we giving it too late?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2839577" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Immunization of healthy adults with live attenuated varicella vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1323943" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419387" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14970064" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Effectiveness over time of varicella vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17360990" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Loss of vaccine-induced immunity to varicella over time.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
